Search results
Showing 196 to 210 of 1209 results for criteria
Awaiting development Reference number: GID-TA11932 Expected publication date: TBC
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)
Evidence-based recommendations on lenvatinib (Lenvima) for untreated advanced hepatocellular carcinoma in adults.
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies.
Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)
Evidence-based recommendations on pazopanib (Votrient) for previously untreated advanced renal cell carcinoma in adults.
Venetoclax for treating chronic lymphocytic leukaemia (TA796)
Evidence-based recommendations on venetoclax (Venclyxto) for chronic lymphocytic leukaemia in adults.
Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]
Awaiting development Reference number: GID-TA11930 Expected publication date: TBC
Awaiting development Reference number: GID-TA11940 Expected publication date: TBC
Awaiting development Reference number: GID-TA11966 Expected publication date: TBC
Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)
This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs
Awaiting development Reference number: GID-TA11910 Expected publication date: TBC
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
Semaglutide 7.2 mg single-dose device for managing overweight and obesity [ID6699]
Awaiting development Reference number: GID-TA11920 Expected publication date: TBC
Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [ID6706]
Awaiting development Reference number: GID-TA11916 Expected publication date: TBC
Levodopa/carbidopa (ND0612) for Parkinson's Disease [ID6727]
Awaiting development Reference number: GID-TA11954 Expected publication date: TBC
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.